News

Gift supports work on a stubborn cancer

News

Clinical trials take innovative approach

Frequent consultation between bench and clinic enhances the effectiveness and impact of Yale Cancer Center’s Phase I Program

It is a simple concept: bench investigators who identify potential cancer therapies, and clinicians who evaluate experimental drugs in patient trials, sitting down together to figure out how each can make the others’ work more effective. And yet, until just the past...

Read more...


Gift supports work on a stubborn cancer

Gift supports work on a stubborn cancer

For a quarter century, Ginny Grunley, her husband Ken Grunley, president and chief executive officer of Grunley Construction, Inc., and their family have been enthusiastic philanthropists. Their determination to help...

Read more...

Gift supports work on a stubborn cancer

New program makes the addiction crisis a priority

The School of Medicine’s Section of General Internal Medicine has established the Yale Program in Addiction Medicine, a multidisciplinary clinical, educational, and research program. The program is intended to enhance...

Read more...

Gift supports work on a stubborn cancer

Yale Cancer Center director led trials for FDA-approved drug

A drug whose clinical testing was led by Charles S. Fuchs, M.D., M.P.H., Richard Sackler and Jonathan Sackler Professor of Medicine (Medical Oncology) and director of Yale Cancer Center, has become the first approved...

Read more...